TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06655766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket-plug technique with putty bone
Description: * Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* putty bone is injected into the socket up to the crest of the bone.~* Collagen plug or sponge is adapted over the graft to occlude the socket~* The plug is then stabilized with absorbable suture material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ice cream cone technique
Description: * Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* A Collagen barrier membrane is then shaped as an ice-cream cone and placed in the extraction socket lining the buccal tissues.~* The socket is then filled with particulate bone graft.~* The upper part of the membrane is then used to cover the socket.~* Absorbable suture is then used to close the socket and stabilize the barrier membrane
Study: NCT06614790

Intervention type: DRUG
Intervention: Niraparib 200/300 MG
Description: We expect to enroll approximately 300 patients from about 10 sites. Treatment part of study.~Part I- looking retrospectively at the time period JAN 2021-MAR 2023. The retrospective data will include patients who are enrolled in niraparib treatment:~* under the EAP (started in JAN 2021, in continuation)~* under the B.50 drug program, which began in January 2022 Of note, the retrospective multi-center observational study will involve about 30 patients treated with niraparib in EAP (FIGO III R0 after PDS included) and patients who were treated with niraparib before starting RWE (about 120 pts) (JAN 2021- MAR 2023) by the drug program B.50 which has been started to adapt on 1st of Jan, 2022.~FIGO III PDS to R0 patients are included to this study. Part II- looking prospectively at the time period APR 2023 to DEC 2025. The prospective data will include patients who are enrolled in niraparib treatment under the B.50 drug program.~The prospective multi-center observational study will i
Study: NCT05894915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open surgery
Description: Open surgery is a traditional surgery method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Laparoscopic surgery is a newly developed minimally invasive method.
Study: NCT05176405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: You-Tube Video: Elissa's EE song
Description: Watch You-Tube video utilizing Entertainment-Education communication strategy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard of Care
Description: Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
Study: NCT05552937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab and Lenalidomide
Description: Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
Study: NCT06517420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kefir consumption
Description: Support and information was received from the Food Technology Department of a university's Experimental Medicine Application and Research Center. It was decided to choose the kefir to be used, which is produced from pasteurized cow's milk, lactase enzyme, probiotic culture (B. Lactis) and kefir culture, will meet the B12 need, contribute to increasing vitality and energy, and has the most suitable content in the market. Kefir, supplied by the researcher, was given to the patients at the end of each session in the amount that the patients should consume for a week, following the cold chain rule. While consuming kefir, it was recommended to gargle it in the mouth, hold it for a while, and then swallow. Patients were contacted for a week after the session to ensure that they applied kefir correctly.
Study: NCT05357651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1410
Description: anti-PD-1 and anti-TIM-3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1410
Description: anti-PD-1 and anti-TIM-3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1410
Description: anti-PD-1 and anti-TIM-3 bispecific antibody
Study: NCT05996718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training program pilot
Description: This intervention for informal caregivers consists of training that will introduce participants to improvisational (improv) theatre and teach its core communication skills.
Study: NCT06514560

Intervention type: DRUG
Intervention: Miltefosine
Description: Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks

Intervention type: DRUG
Intervention: Miltefosine
Description: Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks
Study: NCT06472843

Intervention type: BEHAVIORAL
Intervention: Exercise Intervention
Description: The exercise session is a fitness test using a hand bike, and you will be randomly assigned to one of two exercise sessions. The fitness test and exercise sessions are short (less than 10 minutes).

Intervention type: BEHAVIORAL
Intervention: Exercise Intervention
Description: The exercise session is a fitness test using a hand bike, and you will be randomly assigned to one of two exercise sessions. The fitness test and exercise sessions are short (less than 10 minutes).
Study: NCT06275516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-sensory stimulation immersive VR+ treadmill training
Description: Treadmill training with multi-sensory stimulation immersive VR in VR+treadmill training group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill training
Description: Only treadmill training in treadmill training group
Study: NCT04938154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS ON
Description: The DBS system will be turned on and the patient will be left on their best setting for 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS OFF
Description: The DBS system will be turned off, and will be left off for 3 months.
Study: NCT05056389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administration of oxaliplatin intraperitoneally
Study: NCT04980703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grain moxibustion
Description: Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham grain moxibustion
Description: Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
Study: NCT05152394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05642364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joviality(TM)
Description: 5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inert Virtual Reality
Description: Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
Study: NCT05991297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep sensory assisted rehabilitation
Description: A new PTR plan called deep sensory assisted rehabilitation was created: it was aimed to develop a sensory and deep sense in the adult age group by making use of sensory integration exercises, which are mostly applied in the childhood age group. Whether these exercises are effective on walking and balance will be evaluated. Patients will be dressed in a vest with an equally distributed weight of 4-6 kg according to their weight, and exercises will be done while walking and standing.~- the so-called deep sensory pathway; The patients will be given standing and walking exercises on sand and stone floors, soft floors made of sponge, hard plastic floors with different sizes of grooves and shapes, and hot-cold floors formed by placing hot packs and cold packs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical rehabilitation
Description: Muscle strengthening in all four extremities; strengthening of trunk and abdominal muscles; providing and maintaining joint range of motion; independent and safe standing, turning, and stepping; able to walk alone on flat ground and on different surfaces (such as sloping-handicapped-soil-stone-sand-grass-rough-stepped)
Study: NCT06119139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.6 ml 4% Articaine hydrochloride
Description: 3.6 ml 4% articaine buccal infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.8 ml 4% Articaine hydrochloride
Description: 1.8 ml 4% articaine buccal infiltration
Study: NCT06004427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet program
Description: A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet program
Description: A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training protocols
Description: calisthenic exercises exercises with lower and upper extremity theraband exercises with light dumbbells
Study: NCT05368246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCon
Description: The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
Study: NCT04899986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and Biorepair gel and toothpaste application
Description: Split-mouth application of chlorhexidine gel 1% (quadrants 1 and 4) and Biorepair Periogel (quadrants 2 and 3) after professional dental hygiene. Home oral care will be continued with chlorhexidine 0,12% gel and Biorepair Periogel in the same quadrants, for the following 15 days from the visits, together with the use of Biorepair Parodontogel toothpaste.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene
Description: Use of standard toothpastes for home oral hygiene.
Study: NCT05342077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Reward Training (VR-RT)
Description: Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality-Memory Training (VR-MT)
Description: Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
Study: NCT05385770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X mg + AML Y mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X mg + AML Y' mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X' mg + AML Y mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X' mg + AML Y' mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X' mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X' mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM X' mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AML Y mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AML Y mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AML Y mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AML Y' mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AML Y' mg
Description: tablet, single dose, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AML Y' mg
Description: tablet, single dose, QD, oral administration
Study: NCT06324513

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Crohn's Disease Exclusion Diet (Med-CDED)
Description: The Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) is the exclusion diet (CDED) adapted to the Mediterranean diet pattern. The Med-CDED consists of 2 phases in dietary therapy and a maintenance phase: the first phase lasting 8 weeks, the second phase lasting 16 weeks, and the maintenance phase, which for the purposes of the study will last 28 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crohn's disease exclusion diet (CDED)
Description: The original Crohn's disease exclusion diet, used as a comparator, is widely employed among first-line treatments in clinical practice for inducing remission in pediatric patients with Crohn's disease.
Study: NCT04595747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan and PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib
Description: Given PO
Study: NCT05204004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sunrise
Description: Sunrise (Sunrise SA, Belgium) is a novel integrated digital medicine solution for the diagnosis of OSA allowing the detection of respiratory disorders from the analysis of mandibular movements optimised by an artificial intelligence algorithm machine learning. It is composed of a unique innovative sensor, placed on the chin during the night, connected via Bluetooth to a mobile application which guides the patients for the implementation and allows the transfer of the data collected by the sensor to a certified health host guaranteeing the security and confidentiality of medical data. The analysed data is integrated and automatically transferred into a detailed report made available to doctors via a secure website the day after the test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polygraphy
Description: Polygraphy (Apnoealink-Air, ResMed, Australia) is a commercially available, limited-channel sleep study device which can be used in the home. Many sleep services in the UK already use the ApneaLink Air for routine screening. It is a portable device which consists of a nasal cannula to measure nasal flow and snoring, oximeter to measure pulse and blood oxygen levels, and a chest band to measure respiratory effort. It contains software which allows for the scoring of apnoeas, hypopnoea and arousals.
Study: NCT06051149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal adhesolysis using RACZ Catheter
Description: caudal adhesolysis for patients with failed back surgery syndrome using RACZ Catheter under fluroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal adhesolysis using RACZ Catheter
Description: caudal adhesolysis for patients with failed back surgery syndrome using RACZ Catheter under fluroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal adhesiolysis using NAVI Catheter
Description: caudal adhesolysis for patients with failed back surgery syndrome using NAVI Catheter under fluroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal adhesiolysis using NAVI Catheter
Description: caudal adhesolysis for patients with failed back surgery syndrome using NAVI Catheter under fluroscopy
Study: NCT05982418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Models (3D printing facilities at GSTT)
Description: 3D patient-specific printed models are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D printing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Virtual Models (Innersight Labs)
Description: 3D patient-specific virtual models loaded into Innersight Labs platform are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D visualisation.
Study: NCT04922632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Description: TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience Resolution Methodology (ERM)
Description: ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)
Description: TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: TAU is the existing Duke Health \& Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).